- COA available Certificate of analysis per batch
- USA made Third-party verified
- Same-day dispatch On orders placed before cut-off
- Free shipping over $175 Applied automatically at checkout
About GLP-1 (SMA) 14mg (30)
GLP-1 (SMA) is a GLP-1 receptor agonist peptide, and one of the most sought-after compounds in metabolic and incretin-pathway research. This listing supplies the 14mg (30 tablets) oral tablets for laboratory research use. Every batch is tested to at least 98% purity by HPLC with a certificate of analysis (COA), is USA-made and third-party verified. For research use only; not for human or veterinary use or consumption.
Mechanism of Action
GLP-1 (SMA) is a peptide agonist at the GLP-1 receptor. In preclinical systems researchers use it as a tool compound to study incretin-receptor signalling and how it compares with single-, dual- and triple-receptor research peptides. This describes a research mechanism only.
Preclinical Research
Incretin-receptor agonism has been examined in in-vitro receptor assays and animal metabolic-model research. GLP-1 (SMA) is used to probe receptor activity relative to other incretin research peptides. All referenced work is preclinical and mechanistic; no human data or outcomes are implied.
Research Applications
Typical applications include comparative receptor-signalling studies alongside GLP-2 (TRZ), GLP-3 (RTA) and Cagrilintide, plus metabolic-pathway model work. Browse the full metabolic & incretin research range for related material.
Protocol & Handling
This is an oral tablet format and does not require reconstitution. Store the sealed tablets in a cool, dry place away from direct light and moisture; refrigeration is not required for the sealed product. Handle only in a controlled laboratory setting. For research use only, not for human or veterinary use or consumption.
Frequently asked questions
What is GLP-1 (SMA)?
GLP-1 (SMA) is a GLP-1 receptor agonist peptide. It is supplied strictly for laboratory research use as a tool compound in metabolic and incretin-pathway research.
How does GLP-1 (SMA) work in research models?
In preclinical systems it acts as an agonist at the GLP-1 receptor, so researchers use it to study incretin-receptor signalling. This describes a research mechanism only, not an effect in humans.
What format is this listing?
This listing is the 14mg (30 tablets) oral tablets. GLP-1 (SMA) is stocked in a range of strengths and formats, all linked in the specifications above.
Does GLP-1 (SMA) need to be reconstituted?
No. This oral tablet format is supplied ready as-is and does not require reconstitution.
How should it be stored?
Keep the sealed tablets in a cool, dry place away from direct light, heat and moisture. Refrigeration is not required for the sealed oral product.
What purity is GLP-1 (SMA) tested to?
Each batch is tested to at least 98% purity by HPLC and ships with a certificate of analysis (COA). It is USA-made and independently third-party verified.
What is GLP-1 (SMA) studied alongside?
It is frequently studied alongside other incretin research peptides such as GLP-2 (TRZ) and GLP-3 (RTA), and amylin analogs such as Cagrilintide, in comparative receptor-signalling research.
Is GLP-1 (SMA) intended for human use?
No. It is sold strictly for laboratory and research use only, and is not for human or veterinary use, consumption, diagnosis or treatment.
Research use only
GLP-1 (SMA) 14mg (30) is supplied strictly as a research chemical for laboratory use. It is not for human or veterinary use or consumption, is not a drug, food or supplement, and is not approved by the U.S. Food and Drug Administration for any purpose.
Handle only in a controlled laboratory setting, by qualified personnel, in accordance with applicable law and good laboratory practice.